Observational studyHaematologica2022
Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study.
Abstract readMulticenter StudyObservational Study
In one paragraph
Observational study in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis.Bone marrow transplantation · 2025Pooled it
- Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma.Blood cancer journal · 2026Article
- Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.Blood advances · 2026Article
- Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group.Bone marrow transplantation · 2025Article
- When should we use it? The role of brentuximab vedotin in 2024.Hematology. American Society of Hematology. Education Program · 2024Review
- Article
- Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era - real-world data from Hungary.Annals of hematology · 2023Article
- Did brentuximab vedotin's rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results?Haematologica · 2022Article
- Autologous Stem Cell Transplantation in Hodgkin Lymphoma-Latest Advances in the Era of Novel Therapies.Cancers · 2022Review
- The role of transplantation in Hodgkin lymphoma.Frontiers in oncology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
31 authors.
Amira MaroufDepartment of Hematology, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France; Université de Paris, France; INSERM UMR 1163, Institut Imagine, Paris.
Anne Segolene CottereauUniversité de Paris, France; Department of Nuclear Medicine, Cochin Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris.
Salim KanounCancer Research Center of Toulouse (CRCT), Team 9, INSERM UMR 1037, Toulouse.
Paul DeschampsDepartment of Hematology, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France; Université de Paris.
Michel MeignanLymphoma Academic Research Organization (LYSARC) Lymphoma Study Association Imaging, Hôpital Henri Mondor, Créteil, France; Paris Est University, Créteil.
Patricia FranchiDepartment of Hematology, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France; Université de Paris.
David SibonHematology Department and INSERM U1151, Institut Necker Enfants Malades, Necker University Hospital, AP-HP, Paris.
Clara AntoineLymphoma Academic Research Organization (LYSARC) Lymphoma Study Association Imaging, Hôpital Henri Mondor, Créteil.
Thomas GastinneDepartment of Hematology, Nantes University Hospital, Nantes.
Cecile BorelDepartment of Hematology, Institut universitaire du cancer Toulouse- Oncopole, Toulouse.
Mohammad HammoudLymphoid Malignancies Unit, Hôpital Henri Mondor, Créteil.
Guillaume SicardDepartment of Haematology, Aix-Marseille University, Marseille.
Romane GilleDepartment of Medical Oncology, Centre Léon Bérard, Lyon.
Doriane CavalieriDepartment of Haematology, Centre Hospitalier Universitaire Estaing, Clermont-Ferrand.
Aspasia StamatoullasDepartment of Hematology, Centre Henri Becquerel, Rouen.
Lauriane Filliatre-ClementDepartment of Hematology, Clinique Louis Pasteur, Nancy.
Julien LazaroviciDepartment of Hematology, Institut Gustave-Roussy, Villejuif.
Adrien ChauchetDepartment of Hematology, CHU Besançon, Besançon.
Luc-Matthieu ForneckerStrasbourg University Hospital, Strasbourg, France; INSERM S-1113, Strasbourg, France; Strasbourg University, Faculty of medicine, Strasbourg.
Sandy AmorinDepartment of Hematology, Hôpital Saint Vincent de Paul, Lille.
Mathieu RocquetDepartment of Hematology, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris.
Nicole RausDepartment of Hematology, Hôpital Lyon Sud, Pierre-Bénite, France; Société francophone de greffe de moelle et de thérapie cellulaire.
Barbara BurroniService de pathologie, Hôpital Cochin, APHP, France; Centre de recherche des Cordeliers, Sorbonne University, INSERM, Paris University.
Marie Therese RubioSociété francophone de greffe de moelle et de thérapie cellulaire, France; Department of Hematology, CHRU Nancy, Hôpital Brabois; CNRS UMR 7365, Équipe 6, Biopôle de L'Université de Lorraine, Vandoeuvre-les-Nancy.
Didier BouscaryDepartment of Hematology, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France; Université de Paris, France; Institut Cochin, INSERM U1016, Paris.
Philippe QuittetDepartment of Hematology, University of Montpellier, Montpellier.
Rene Olivier CasasnovasDepartment of Hematology, Dijon University Hospital, Dijon, France; INSERM UMR 1231 CHU Dijon.
Pauline BriceDepartment of Hematology, CHU Paris-GH St-Louis Lariboisière F-Widal - Hôpital Saint-Louis, Paris.
Herve GhesquieresDepartment of Hematology, Centre Hospitalier Lyon Sud, Pierre-Bénite.
Jérôme TamburiniDepartment of Hematology, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France; Université de Paris, France; Institut Cochin, INSERM U1016, Paris, France; Translational Research Centre in Onco-hematology, Faculty of Medicine, University of Geneva, 1211, Geneva 4.
Benedicte DeauDepartment of Hematology, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France; Université de Paris. benedicte.deau-fischer@aphp.fr.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Hematopoietic Stem Cell TransplantationHodgkin DiseaseImmunoconjugatesBrentuximab VedotinHumansSalvage TherapyStem Cell TransplantationTransplantation, AutologousBrentuximab VedotinImmunoconjugates
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.